These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 24039611)
21. Caring for Machado-Joseph disease: current understanding and how to help patients. D'Abreu A; França MC; Paulson HL; Lopes-Cendes I Parkinsonism Relat Disord; 2010 Jan; 16(1):2-7. PubMed ID: 19811945 [TBL] [Abstract][Full Text] [Related]
22. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007 [TBL] [Abstract][Full Text] [Related]
23. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Warrick JM; Paulson HL; Gray-Board GL; Bui QT; Fischbeck KH; Pittman RN; Bonini NM Cell; 1998 Jun; 93(6):939-49. PubMed ID: 9635424 [TBL] [Abstract][Full Text] [Related]
25. Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report. Bettencourt C; Santos C; Coutinho P; Rizzu P; Vasconcelos J; Kay T; Cymbron T; Raposo M; Heutink P; Lima M BMC Neurol; 2011 Oct; 11():131. PubMed ID: 22023810 [TBL] [Abstract][Full Text] [Related]
26. Prenatal diagnosis of Machado-Joseph disease/Spinocerebellar Ataxia Type 3 in Taiwan: early detection of expanded ataxin-3. Tsai HF; Liu CS; Chen GD; Lin ML; Li C; Chen YY; Wang BT; Hsieh M J Clin Lab Anal; 2003; 17(5):195-200. PubMed ID: 12938149 [TBL] [Abstract][Full Text] [Related]
27. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis. Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985 [TBL] [Abstract][Full Text] [Related]
28. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684 [TBL] [Abstract][Full Text] [Related]
29. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100 [TBL] [Abstract][Full Text] [Related]
30. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066 [TBL] [Abstract][Full Text] [Related]
31. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Warrick JM; Morabito LM; Bilen J; Gordesky-Gold B; Faust LZ; Paulson HL; Bonini NM Mol Cell; 2005 Apr; 18(1):37-48. PubMed ID: 15808507 [TBL] [Abstract][Full Text] [Related]
32. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance. Li X; Liu H; Fischhaber PL; Tang TS Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252 [TBL] [Abstract][Full Text] [Related]
33. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Chen ZS; Huang X; Talbot K; Chan HYE Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212 [TBL] [Abstract][Full Text] [Related]
34. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Jung J; Xu K; Lessing D; Bonini NM Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548 [TBL] [Abstract][Full Text] [Related]
35. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Perez MK; Paulson HL; Pittman RN Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285 [TBL] [Abstract][Full Text] [Related]
36. A genetic model for human polyglutamine-repeat disease in Drosophila melanogaster. Bonini NM Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1057-60. PubMed ID: 10434305 [TBL] [Abstract][Full Text] [Related]
37. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213 [TBL] [Abstract][Full Text] [Related]
38. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371 [TBL] [Abstract][Full Text] [Related]
39. [Mechanisms to control degradation of polyglutamine-containing protein]. Nakayama K Rinsho Shinkeigaku; 2003 Nov; 43(11):906-8. PubMed ID: 15152500 [TBL] [Abstract][Full Text] [Related]
40. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context. Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]